AGENUS INC (AGEN) Latest Company News

Oct 8, 2026, 11:30 UTC
Armenia’s Ministry of Health granted marketing authorizations for Agenus’ Botvymo (botensilimab) and Evamplix (balstilimab), approved in combination to treat adults with previously treated MSS metastatic colorectal cancer without active liver metastases.
Source:
- businesswire.com
Oct 3, 2026, 14:50 UTC
Agenus Inc. announced three-year follow-up results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab, reporting 48% estimated three-year survival, at IGCS 2026.
Source:
- businesswire.com
Oct 2, 2026, 13:00 UTC
Agenus Inc. announced that two posters on botensilimab plus balstilimab and agenT-797 research in colorectal cancer were accepted for presentation at the SITC 2026 Annual Meeting in Phoenix, Arizona, November 4-8, 2026.
Source:
- businesswire.com
Sep 10, 2026, 11:30 UTC
Agenus Inc. announced that a poster on botensilimab plus balstilimab in recurrent ovarian cancer was accepted for presentation at the IGCS Annual Global Meeting in Montreal, Canada, on October 1-3, 2026.
Source:
- businesswire.com
Aug 26, 2026, 14:05 UTC
Agenus announced the peer-reviewed publication of updated results from the Phase 2 NEST trial of neoadjuvant botensilimab and balstilimab in resectable colon cancer, reporting deep pathologic responses and no observed recurrences.
Source:
- businesswire.com
Aug 18, 2026, 00:00 UTC
Agenus Inc. amended and restated its existing promissory note with Ocean 1181 LLC, extending the maturity to November 30, 2029, maintaining a 13.0% annual interest rate, and adding a $247,500 extension fee, half of which is payable in common stock.
Aug 6, 2026, 11:30 UTC
Agenus Inc. advanced its Phase 3 ROBBIN trial of botensilimab plus balstilimab in neoadjuvant MSS colon cancer.
Source:
- businesswire.com
Jul 13, 2026, 14:02 UTC
Agenus announced a shift in development focus to a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab (BOT/BAL) in high-risk stage 2 and stage 3 microsatellite stable colon cancer.
Source:
- marketbeat.com
Jul 13, 2026, 13:48 UTC
Agenus completed a securities purchase agreement for a private placement of $85 million, with warrants that could raise an additional $255 million, for total potential proceeds of up to $340 million.
Source:
Jul 6, 2026, 00:00 UTC
Agenus Inc amended its $5.09 million senior subordinated promissory notes, extending the maturity date from June 20, 2026 to February 18, 2027, and extended the expiration of existing warrants while issuing new warrants for 56,525 common shares.

AGEN

Armenia’s Ministry of Health granted marketing authorizations for Agenus’ Botvymo (botensilimab) and Evamplix (balstilimab), approved in combination to treat adults with previously treated MSS metastatic colorectal cancer without active liver metastases.

Agenus Inc. announced three-year follow-up results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab, reporting 48% estimated three-year survival, at IGCS 2026.

Agenus Inc. announced that two posters on botensilimab plus balstilimab and agenT-797 research in colorectal cancer were accepted for presentation at the SITC 2026 Annual Meeting in Phoenix, Arizona, November 4-8, 2026.

Agenus Inc. announced that a poster on botensilimab plus balstilimab in recurrent ovarian cancer was accepted for presentation at the IGCS Annual Global Meeting in Montreal, Canada, on October 1-3, 2026.

Agenus announced the peer-reviewed publication of updated results from the Phase 2 NEST trial of neoadjuvant botensilimab and balstilimab in resectable colon cancer, reporting deep pathologic responses and no observed recurrences.

Agenus Inc. amended and restated its existing promissory note with Ocean 1181 LLC, extending the maturity to November 30, 2029, maintaining a 13.0% annual interest rate, and adding a $247,500 extension fee, half of which is payable in common stock.

Agenus Inc. advanced its Phase 3 ROBBIN trial of botensilimab plus balstilimab in neoadjuvant MSS colon cancer.

Agenus announced a shift in development focus to a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab (BOT/BAL) in high-risk stage 2 and stage 3 microsatellite stable colon cancer.

Agenus completed a securities purchase agreement for a private placement of $85 million, with warrants that could raise an additional $255 million, for total potential proceeds of up to $340 million.

Agenus Inc amended its $5.09 million senior subordinated promissory notes, extending the maturity date from June 20, 2026 to February 18, 2027, and extended the expiration of existing warrants while issuing new warrants for 56,525 common shares.